Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ironwood Pharmaceuti (IRWD)

Ironwood Pharmaceuti (IRWD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,790,331
  • Shares Outstanding, K 163,650
  • Annual Sales, $ 389,520 K
  • Annual Income, $ 106,180 K
  • 60-Month Beta 1.25
  • Price/Sales 4.33
  • Price/Cash Flow 14.34
  • Price/Book 3.30
Trade IRWD with:

Options Overview Details

View History
  • Implied Volatility 52.63% ( -4.63%)
  • Historical Volatility 37.75%
  • IV Percentile 38%
  • IV Rank 25.61%
  • IV High 116.07% on 04/12/21
  • IV Low 30.79% on 12/22/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 673
  • Open Int (30-Day) 5,286

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate 0.31
  • Number of Estimates 3
  • High Estimate 0.36
  • Low Estimate 0.28
  • Prior Year 0.36
  • Growth Rate Est. (year over year) -13.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.93 +4.07%
on 12/20/21
12.11 -6.07%
on 01/04/22
+0.13 (+1.11%)
since 12/17/21
3-Month
10.59 +7.41%
on 11/30/21
13.56 -16.14%
on 10/20/21
-2.06 (-15.36%)
since 10/19/21
52-Week
8.78 +29.53%
on 02/26/21
14.27 -20.29%
on 08/12/21
+0.40 (+3.60%)
since 01/19/21

Most Recent Stories

More News
Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided updated financial guidance for full year 2021 and announced financial guidance for full year 2022. The results...

IRWD : 11.38 (+4.02%)
Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday,...

IRWD : 11.38 (+4.02%)
Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become...

IRWD : 11.38 (+4.02%)
Ironwood (IRWD) Q3 Earnings Top, Sales Hurt by Lower Price

Ironwood (IRWD) witnesses flat year-over-year sales as growth in demand for Linzess gets partially offset by lower net price of the drug. The company maintains revenue guidance. Stock down.

AZN : 59.78 (-0.10%)
IRWD : 11.38 (+4.02%)
ABBV : 136.46 (-0.23%)
XNCR : 36.27 (+3.36%)
Ironwood Pharmaceuticals (IRWD) Q3 Earnings Surpass Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of 6.45% and -1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

IRWD : 11.38 (+4.02%)
Ironwood: Q3 Earnings Snapshot

BOSTON (AP) _ Ironwood Pharmaceuticals Inc. (IRWD) on Thursday reported third-quarter profit of $55.8 million.

IRWD : 11.38 (+4.02%)
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported financial results for third quarter 2021.

IRWD : 11.38 (+4.02%)
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that it is expanding its pipeline by entering into a collaboration and license option agreement with COUR...

IRWD : 11.38 (+4.02%)
Ironwood Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Ironwood Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $12.75, changing hands for $12.81/share. When a stock reaches the target an analyst...

IRWD : 11.38 (+4.02%)
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting and Postgraduate...

IRWD : 11.38 (+4.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Company's first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome...

See More

Key Turning Points

3rd Resistance Point 12.27
2nd Resistance Point 12.01
1st Resistance Point 11.47
Last Price 11.38
1st Support Level 10.67
2nd Support Level 10.41
3rd Support Level 9.87

See More

52-Week High 14.27
Fibonacci 61.8% 12.17
Fibonacci 50% 11.53
Last Price 11.38
Fibonacci 38.2% 10.88
52-Week Low 8.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar